- First patient enrolled in long term safety study in November 2017
- Pivotal efficacy data for M207 published in October 2017
- Allowed patent application to be issued in March 2018 extends proprietary position for M207 to 2037
FREMONT, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”), today announced financial results for the fourth quarter ended December 31, 2017.
“The fourth quarter continued to see strong execution in bringing M207 to market. We are pleased with the enrollment in our open label, Long-Term Safety Study, and note that we now have 28 sites up and running. We remain confident that we will hit our targets of having 100 subjects on study drug by the end of the first quarter and 250 by the end of the second quarter,” commented John Walker, Chairman and Chief Executive Officer.
“Our efforts to highlight our efficacy data to the clinical community continues, most notably by the publication of our pivotal data in Cephalalgia in October,” Mr. Walker continued. “The issuance of our new patent on the use of M207 to treat migraine and cluster headaches is also significant as it provides intellectual property protection through 2037.”
Recent Business Highlights and Clinical Update
- In October 2017, Zosano announced that Cephalalgia had published the results from our ZOTRIP Phase 2/3 efficacy trial.
- In October 2017, Zosano announced the appointment of Kenneth R. Greathouse to the Board of Directors. Mr. Greathouse is a seasoned pharmaceutical executive with over 40 years of experience in sales, marketing, business development and commercial operations.
- In October 2017, Zosano entered into a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC providing for the purchase of up to $35 million worth of our common stock over a 30-month period, subject to certain limitations.
- In November 2017, Zosano announced initiation of our long-term safety study evaluating M207.
- In November 2017, Zosano presented at the 29th Annual Piper Jaffray Health Conference.
- In December 2017, Zosano received Notice of Allowance from the United States Patent and Trademark Office for our patent application directed to M207. This newly allowed application will issue on March 20, 2018 as U.S. Pat. No. 9,918,932 and will expire in 2037.
- In January 2018, Zosano effected a 1-for-20 reverse stock split of our outstanding shares of common stock and regained compliance with Nasdaq Listing Rule 5550(a)(2) as of the close of trading on February 8, 2018.
Financial Results for the Fourth Quarter Ended December 31, 2017
- Zosano reported a net loss for the fourth quarter of 2017 of $7.5 million, or $3.80 per share on a basic and diluted basis, compared with a net loss of $7.7 million, or $9.23 per share on a basic and diluted basis, for the same quarter in 2016.
- Research and development expenses for the fourth quarter of 2017 were $5.5 million, compared with $5.4 million for the same quarter in 2016. R&D expenses for the fourth quarter of 2017 and 2016 were essentially unchanged.
- General and administrative (G&A) expenses for the fourth quarter of 2017 was $1.8 million, compared with $2.0 million in 2016. The decrease of $0.2 million was due to the reduction in general corporate expenses.
- As of December 31, 2017, we had cash, cash equivalents and marketable securities of $11.7 million, debt of $6.7 million and 2.0 million common shares outstanding.
- All share and per share information in this press release has been retroactively adjusted to give effect to the reverse stock split.
Financial Results for the Fiscal Year Ended December 31, 2017
- Zosano reported a net loss for the year 2017 of $29.1 million, or $16.82 per share on a basic and diluted basis, compared with a net loss of $29.8 million, or $43.36 per share on a basic and diluted basis, for the year 2016.
- Research and development expenses for the year 2017 were $20.2 million, compared with $20.5 million in 2016. In 2017, our research and development efforts and resources focused primarily on advancing the development of M207. Expenses in 2016 primarily consisted of M207 ZOTRIP trial, Phase 1 clinical trial and related preclinical toxicology studies.
- General and administrative (G&A) expenses for the year 2017 were $8.2 million, essentially unchanged from the same year ended 2016.
About Migraine
Migraine is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation. Migraine symptoms can include moderate to severe headache pain combined with nausea and vomiting, or abnormal sensitivity to light and sound. According to the Migraine Research Foundation, migraine affects 30 million men, women and children in the United States. Most migraines last between four and 24 hours, but some last as long as three days. According to published studies, 63% of migraine patients experience between one and four migraines per month. According to Decision Resources, prescription drug sales for migraine in the top seven countries were estimated to be $3.3 billion in 2015, and are expected to grow to $4.4 billion in 2020. Triptans, a family of tryptamine-based drugs first sold in the 1990s, account for almost 75% of anti-migraine therapies prescribed at office visits.
About M207
M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano's proprietary ADAM technology. Zosano's ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan. Our ADAM technology delivers drug by abrading the stratum corneum and allowing drug to be absorbed into the microcapillary system of the skin. In February 2017, the Company announced statistically significant results from the ZOTRIP trial, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours. In November 2017, the Company announced the initiation of its long term safety study evaluating M207.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology. The Company previously announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine, and has initiated a long term safety study of M207. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. The Company anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.
Zosano Contact:
Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200
| ZOSANO PHARMA CORPORATION | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (in thousands, except per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||
| Revenue: | $ | - | $ | - | $ | - | $ | - | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 5,516 | 5,413 | 20,188 | 20,457 | |||||||||||
| General and administrative | 1,836 | 2,039 | 8,182 | 8,176 | |||||||||||
| Total operating expenses | 7,352 | 7,452 | 28,370 | 28,633 | |||||||||||
| Loss from operations | (7,352 | ) | (7,452 | ) | (28,370 | ) | (28,633 | ) | |||||||
| Other income (expenses): | |||||||||||||||
| Interest expense, net | (134 | ) | (241 | ) | (742 | ) | (1,192 | ) | |||||||
| Other income (expense), net | (3 | ) | (56 | ) | 7 | (7 | ) | ||||||||
| Net loss | $ | (7,489 | ) | $ | (7,749 | ) | $ | (29,105 | ) | $ | (29,832 | ) | |||
| Net loss per common share ̶ basic and diluted | $ | (3.80 | ) | $ | (9.23 | ) | $ | (16.82 | ) | $ | (43.36 | ) | |||
| Weighted-average shares used in computing net loss per common share ̶ basic and diluted | 1,970 | 840 | 1,730 | 688 | |||||||||||
| ZOSANO PHARMA CORPORATION | |||||
| SELECTED CONDENSED CONSOLIDATED BALANCE SHEETS DATA | |||||
| (in thousands) | |||||
| December 31, | December 31, | ||||
| 2017 | 2016 | ||||
| Cash, cash equivalents and marketable securities | $ | 11,651 | $ | 15,003 | |
| Total current assets | 13,393 | 15,276 | |||
| Total assets | 18,000 | 20,906 | |||
| Secured promissory note | 6,687 | 12,542 | |||
| Total liabilities | 10,952 | 16,421 | |||
| Stockholders’ equity | 7,048 | 4,485 | |||